Appletree Medical Group

appletreemedicalgroup.com

For almost 30 years, Appletree Medical Group has focused on improving community healthcare. Thanks to years of continuous innovation, we have grown to become one of the largest multidisciplinary community health groups in Canada, preferred by both patients and health professionals alike. Whether by visiting one of our 75 medical centres or telemedicine sites, or connecting through our Virtual Care app, Appletree patients are given greater control over their healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

INVIVOSCRIBE ANNOUNCES FDA APPROVAL OF THE LEUKOSTRAT CDX FLT3 MUTATION ASSAY TO SELECT PATIENTS WITH FLT3-ITD POSITIVE AML

PRNewswire | July 27, 2023

news image

Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib). The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with this newly approved targeted...

Read More

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

Labiotech.eu | January 27, 2020

news image

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

news image

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More

Industrial Impact

ECOLOGICAL LABORATORIES, INC. ANNOUNCES ACQUISITION OF TOMCO CHEMICAL TO BOLSTER REACH INTO HOG FARMING WASTE MANAGEMENT.

Ecological Laboratories, Inc. | July 08, 2022

news image

Ecological Laboratories, Inc. a Biotechnology company that develops and manufactures novel, proprietary, liquid microbial formulations capable of solving many of the most challenging environmental problems, announced that it has acquired TOMCO Chemical. TOMCO Chemical has provided bacterial products specifically to breakdown solids and reduce odors for Hog Farms in the United States. "We are thrilled to bring together the TOMCO team with Ecological, whic...

Read More
news image

Medical

INVIVOSCRIBE ANNOUNCES FDA APPROVAL OF THE LEUKOSTRAT CDX FLT3 MUTATION ASSAY TO SELECT PATIENTS WITH FLT3-ITD POSITIVE AML

PRNewswire | July 27, 2023

Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib). The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with this newly approved targeted...

Read More
news image

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

Labiotech.eu | January 27, 2020

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More
news image

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More
news image

Industrial Impact

ECOLOGICAL LABORATORIES, INC. ANNOUNCES ACQUISITION OF TOMCO CHEMICAL TO BOLSTER REACH INTO HOG FARMING WASTE MANAGEMENT.

Ecological Laboratories, Inc. | July 08, 2022

Ecological Laboratories, Inc. a Biotechnology company that develops and manufactures novel, proprietary, liquid microbial formulations capable of solving many of the most challenging environmental problems, announced that it has acquired TOMCO Chemical. TOMCO Chemical has provided bacterial products specifically to breakdown solids and reduce odors for Hog Farms in the United States. "We are thrilled to bring together the TOMCO team with Ecological, whic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us